Is there a patient for whom you’d prefer a single-agent TKI?Moshe, you advocate following the patient with a close eye and deferring initiation of systemic therapy with your approach of observation and surveillance. If we think the patient doesn’t have to be treated quickly, is there a ...
Discussion of single-agent systemic therapy will thus relate only to these lesions of celomic epithelial origin (henceforward referred to simply as ovarian carcinoma).doi:10.1007/978-1-4613-2561-1_7J. Tate ThigpenSpringer USThigpen T (1985) Single agent chemotherapy in the management of ovarian ...
Systemic therapy with cytostatic agents has been widely used in the management of inoperable adenocarcinoma of the lung (ACL). However, chemotherapy for this tumor type remains experimental, and the prognosis is still poor. Thus, the literature on single-agent chemotherapy was reviewed in order to...
Single-agentil-2 has attracted much attention over the past several years. A number of randomized trials and many phaseiitrials investigating single-agentil-2 suggest that this systemic treatment produces durable responses in melanoma patients. Given the dismal survival of patients with meta-static ...
221: Single-Agent Chemotherapy with Docetaxel Significantly Reduces PSA Levels in Patients with High-Grade Localized Prostate Cancers AP Berger,M Niescher,J Bektic,... - 《Journal of Urology》 被引量: 0发表: 2005年 Considerations for second-line therapy of non-small cell lung cancer. For ...
Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months. J Clin Oncol. 2010;28(Suppl 15):405 (abstract 5060). Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line ...
DREAMM-2 (NCT03525678) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, in a frozen-liquid presentation in patients with relapsed/refractory multiple myeloma (RRMM). Along...
as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. Cervical Cancer ...
Ibrutinib is approved in the EU, USA, and other countries for patients with mantle cell lymphoma who received one previous therapy. In a previous phase 2 study with single-agent ibrutinib, the proportion of patients who achieved an objec... ML Wang,H Lee,H Chuang,... - 《Lancet Oncology...
Generally, locoregional surgery is curative and systemic therapy is not indicated. We evaluated the activity and toxicity profile of tomotherapy concomitant with Cetuximab, followed by Cetuximab as single agent therapy in a patient affected by unresectable, locally advanced cutaneous SCC. Case ...